Michel Demare, who took over in April, will be in charge of the hunt for a replacement for Soriot, who has led the FTSE 100 pharmaceuticals giant for more than a decade.
Michel Demare, who took over in April, will be in charge of the hunt for a replacement for Soriot, who has led the FTSE 100 pharmaceuticals giant for more than a decade.
Can a CEO be worth $9 billion? Without a clear succession plan, investors should prepare for further swings. Today AstraZeneca’s shares are worth nearly twice that amount, and the group has thrived thanks to blockbusters like breast cancer treatment Lynparza, and bold M&A, such as the $39 billion purchase of rare disease specialist Alexion in the middle of the pandemic.